Blockhuys, S.; Hildesjö, C.; Olsson, H.; Vahdat, L.; Wittung-Stafshede, P.
Evaluation of ATOX1 as a Potential Predictive Biomarker for Tetrathiomolybdate Treatment of Breast Cancer Patients with High Risk of Recurrence. Biomedicines 2021, 9, 1887.
https://doi.org/10.3390/biomedicines9121887
AMA Style
Blockhuys S, Hildesjö C, Olsson H, Vahdat L, Wittung-Stafshede P.
Evaluation of ATOX1 as a Potential Predictive Biomarker for Tetrathiomolybdate Treatment of Breast Cancer Patients with High Risk of Recurrence. Biomedicines. 2021; 9(12):1887.
https://doi.org/10.3390/biomedicines9121887
Chicago/Turabian Style
Blockhuys, Stéphanie, Camilla Hildesjö, Hans Olsson, Linda Vahdat, and Pernilla Wittung-Stafshede.
2021. "Evaluation of ATOX1 as a Potential Predictive Biomarker for Tetrathiomolybdate Treatment of Breast Cancer Patients with High Risk of Recurrence" Biomedicines 9, no. 12: 1887.
https://doi.org/10.3390/biomedicines9121887
APA Style
Blockhuys, S., Hildesjö, C., Olsson, H., Vahdat, L., & Wittung-Stafshede, P.
(2021). Evaluation of ATOX1 as a Potential Predictive Biomarker for Tetrathiomolybdate Treatment of Breast Cancer Patients with High Risk of Recurrence. Biomedicines, 9(12), 1887.
https://doi.org/10.3390/biomedicines9121887